{
  "id": 17022953,
  "title": "Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones",
  "url": "https://urgent.news/2026/10/29/takeda-announces-fy2026-first-half-results-highlighting-launch",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T06:40:56.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/pmn/business-wire-news-releases-pmn/takeda-announces-fy2026-first-half-results-highlighting-launch-momentum-and-pipeline-milestones"
  },
  "original_language": "en",
  "account": null,
  "summary": "ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S. Food & Drug Administration (FDA) Priority Review and European Medicines Agency (EMA) review Late-stage pipeline continues to advance FY2026 full-year outlook upgraded to reflect foreign exchange (FX) […]",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}